www.fdanews.com/articles/177985-arch-presents-data-for-ac5-topical-hemostatic-device-from-first-clinical-study
Arch Presents Data for AC5 Topical Hemostatic Device from First Clinical Study
August 15, 2016
Arch Therapeutics said that a recent clinical study shows its AC5 hemostatic device met its primary and secondary endpoints.
The device is designed to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
The clinical study consisted of 46 patients, including 10 who were taking antiplatelet monotherapy. — Cynthia Jessup